[Prospective study of early application of immune-enhanced enteral nutrition and recombined human growth hormone on patients with gastric neoplasms after total gastrectomy].

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

To explore the effect of immune-enhanced enteral nutrition (IEN) together with recombined human growth hormone (rhGH) on patients after total gastrectomy.

Who Took Part

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

Forty-eight patients after total gastrectomy were randomly divided into EN group (n=16), IEN group (n=16) and IEN+ rhGH(n=16) group.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nitrogen balance, nutritional status, immune function and lassitude degree were compared among 3 groups.

What Was Measured

PubMed files the paper under topics including Enteral Nutrition, Fat Emulsions, Intravenous, Gastrectomy, Human Growth Hormone, Postoperative Period, Recombinant Proteins and Stomach Neoplasms.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2007 (Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery), a journal based in China.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.